Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
Stopped The study stopped due to insufficient accrual (only two patients were included), and the sponsor has decided on its premature termination.
Conditions
- Locally Advanced Breast Cancer
- Metastatic Breast Cancer
Interventions
- DRUG: Trastuzumab deruxtecan
Sponsor
Spanish Breast Cancer Research Group
Collaborators